Effectiveness and safety of a therapeutic vaccine against angiotensin II receptor type 1 in hypertensive animals

Hypertension

Volumn 61, Issue 2, 2013, Pages 408-416

  Chen, Xiao ^a   Qiu, Zhihua ^a   Yang, Shijun ^a   Ding, Dan ^a   Chen, Fen ^a   Zhou, Yanzhao ^a   Wang, Min ^a   Lin, Jibin ^a   Yu, Xian ^a   Zhou, Zihua ^a   Liao, Yuhua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

angiotensin II; angiotensin II type 1 receptor; angiotensin II type 1 receptor autoantibodies; hypertension; vaccine

Indexed keywords

ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; ATRQ BETA 001 VACCINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C ALPHA; UNCLASSIFIED DRUG; VALSARTAN;

ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BACTERIOPHAGE; BINDING KINETICS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; COMPETITIVE INHIBITION; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HYPERTENSION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; UPREGULATION; VACCINATION; VIRUS LIKE AGENT;

ANIMALS; BLOOD PRESSURE; HYPERTENSION; MICE; PHOSPHORYLATION; RATS; RATS, INBRED SHR; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; VACCINATION; VACCINES;

EID: 84873056015     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.201020     Document Type: Article

References (29)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223. (Pubitemid 40138015)
2. Bachmann MF, Dyer MR. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov. 2004;3:81-88. (Pubitemid 38088700)
3. Brown MJ. Success and failure of vaccines against renin-angiotensin system components. Nat Rev Cardiol. 2009;6:639-647.
4. Zhu F, Zhou Z, Liao Y. The renin-angiotensin system and therapeutic vaccines for hypertension. Curr Opin Investig Drugs. 2008;9:286-294. (Pubitemid 351323382)
5. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
6. Camelia BG, Sadashiva K. Model of the whole rat AT1 receptor and the ligand-binding site. J Mol Model. 2006;12:325-337.
7. Zhu F, Liao YH, Li LD, Cheng M, Wei F, Wei YM, Wang M. Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats. Cell Mol Immunol. 2006;3:107-114.
8. Tatsuhiko Azegami, Hiroyuki Sasamura, Kaori Hayashi, Hiroshi Itoh. Vaccination against the angiotensin type 1 receptor for the prevention of L-NAME-induced nephropathy. Hypertension Research. 2012;35:492-499.
9. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10:787-796.
10. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, Volk HD, Stocker H, Müller P, Jennings GT, Wagner F, Bachmann MF. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet. 2008;371:821-827. (Pubitemid 351323893)
11. Lászlò Hunyady, Kevin J. Catt. Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II. Mol. Endocrinol.2006;20:953-970.
12. Thway TM, Shlykov SG, Day MC, Sanborn BM, Gilstrap LC 3rd, Xia Y, Kellems RE. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation. 2004;110:1612-1619. (Pubitemid 39297984)
13. Xia Y, Zhou CC, Ramin SM, Kellems RE. Angiotensin receptors, autoimmunity, and preeclampsia. J Immunol. 2007;179:3391-3395.
14. Herse F, Verlohren S, Wenzel K, Pape J, Muller DN, Modrow S, Wallukat G, Luft FC, Redman CW, Dechend R. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension. 2009;53:393-398.
15. Zhou CC, Irani RA, Zhang Y, Blackwell SC, Mi T, Wen J, Shelat H, Geng YJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia. Circulation. 2010;121:436-444.
16. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008;14:855-862.
17. Sanders J, Miguel RN, Furmaniak J, Smith BR. TSH receptor monoclonal antibodies with agonist, antagonist, and inverse agonist activities. Meth Enzymol. 2010;485:393-420.
18. Terry F. Davies, Takao Ando, Reigh-Yi Lin, Yaron Tomer, Rauf Latif. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J. Clin. Invest. 2005;115:1972-1983.
19. Pascual VH, Oparil S, Eldridge JH, Jin H, Bost KL, Pascual DW. Spontaneously hypertensive rat: lymphoid depression is age dependent and mediated via a mononuclear cell subpopulation. Am J Physiol. 1992;262(1 pt 2):R1-R7.
20. Fogari R, Zoppi A, Mugellini A, Maffioli P, Lazzari P, Derosa G. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. Hypertens Res. 2011;34:1321-1326.
21. Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, Sjogren KG, Hjalmarson A, Muller-Esterl W, Hoebeke J. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens. 2000;18:945-953. (Pubitemid 30459497)
22. Fu ML, Schulze W, Wallukat G, Hjalmarson A, Hoebeke J. Functional epitope analysis of the second extracellular loop of the human heart muscarinic acetylcholine receptor. J Mol Cell Cardiol. 1995;27:427-436.
23. Unal H, Jagannathan R, Bhat MB, Karnik SS. Ligand-specific Conformation of Extracellular Loop-2 in the Angiotensin II Type 1 Receptor. J. Biol. Chem. 2010;285: 16341-16350.
24. Deodhar SD, Haas E, Goldblatt H. Production of antirenin to homologous renin and its effect of experimental renal hypertension. J Exp Med. 1964;119:425-432.
25. Michel JB, Sayah S, Guettier C, Nussberger J, Philippe M, Gonzalez MF, Carelli C, Galen FX, Menard J, Corvol P. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation. 1990;81:1899-1910. (Pubitemid 20183839)
26. Michel JB, Guettier C, Philippe M, Galen FX, Corvol P, Menard J. Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci U S A. 1987;204:281-288.
27. Gardiner SM, Auton TR, Downham MR, Sharp HL, Kemp PA, March JE, Martin H, Morgan PJ, Rushton A, Bennett T, Glover JF. Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. Br J Pharmacol. 2000;129:1178-1182. (Pubitemid 30153974)
28. Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR, Glover JF. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci. 2004;107:167-173. (Pubitemid 39070933)
29. Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, Nief V, Schellekens C, Sladko K, Roubicek K, Pfister T, Rettenbacher M, Volk HD, Wagner F, Müller P, et al. A vaccine for hypertension based on viruslike particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens. 2007;25:63-72. (Pubitemid 44885665)